2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 968

Circulating PR3-Specific B Cells in Patients with Active ANCA-Associated Vasculitis
Abstract Number: 488

Citrullinated Antigens with Multiple Citruline Similar Motif Could Be Used for RA Diagnosis
Abstract Number: 7

Citrullination of Interleukin 6 Augments Its Pro-inflammatory Capacity and Signaling Potency Through Interleukin-6 Receptor in Rheumatoid Arthritis
Abstract Number: 2859

Citrulline Reactive B Cells Are Present in the Lungs of Early Untreated RA
Abstract Number: 8

CKD-506, a Selective Histone Deacetylase (HDAC) 6 Inhibitor, Regulates Inflammatory Responses Through NF-kB and AP-1 Signaling
Abstract Number: 1068

Classical Monocytes from African Ancestry Patients with Systemic Sclerosis Show Transcription and Energy Regulation Gene Expression Signatures
Abstract Number: 365

Classifying Pseudogout Using Machine Learning Approaches with Electronic Health Record Data
Abstract Number: 1779

CLEC5A/MDL-1 Is Critical for Inflammatory Arthritis and Skin Inflammation
Abstract Number: 2772

Clinical and Biological Changes in Rheumatoid Arthritis Patients Exposed to an Anti-inflammatory Diet
Abstract Number: 494

Clinical and Biomarker Factor Associations with Symptoms and Future Development of RA: TIP-RA Collective
Abstract Number: 2907

Clinical and Functional Outcomes Among Rheumatoid Arthritis Patients Switching Between JAK1-Selective Inhibitor Upadacitinib and Adalimumab Following Insufficient Response
Abstract Number: 143

Clinical and Genetic Factors Associated with Thrombosis or Pregnancy Morbidity of Antiphospholipid Antibody-Positive Systemic Lupus Erythematosus Patients
Abstract Number: 675

Clinical and Serological Lupus Activity Before and After Developing End Stage Renal Disease
Abstract Number: 1590

Clinical and Sociodemographic Associates of Depression and Anxiety in Systemic Lupus Erythematosus
Abstract Number: 684

Clinical Biomarkers at Renal Flare Are Associated with Histologic Changes in Repeat Renal Biopsy in Patients with Biopsy-proven Lupus Nephritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].